China Medical System Holdings Limited (0867.HK)
HKD 7.36
(-0.67%)
HKD 7.36
(-0.67%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 2.92 Billion CNY | -8.01% |
| 2022 | 3.84 Billion CNY | 7.01% |
| 2021 | 3.7 Billion CNY | 15.22% |
| 2020 | 3.05 Billion CNY | 13.71% |
| 2019 | 2.74 Billion CNY | 21.37% |
| 2018 | 2.2 Billion CNY | 8.39% |
| 2017 | 2.08 Billion CNY | 20.01% |
| 2016 | 1.69 Billion CNY | 49.03% |
| 2015 | 1.16 Billion CNY | -2.02% |
| 2014 | 914.03 Million CNY | 64.23% |
| 2013 | 649.85 Million CNY | 14.23% |
| 2012 | 590.08 Million CNY | 38.05% |
| 2011 | 459.89 Million CNY | 88.35% |
| 2010 | 244.17 Million CNY | 25.08% |
| 2009 | 200.25 Million CNY | 45.81% |
| 2008 | 133.88 Million CNY | 65.79% |
| 2007 | 82.86 Million CNY | 73.34% |
| 2006 | 46.59 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 471.51 Million CNY | -0.32% |
| 2024 Q2 | 471.51 Million CNY | 0.0% |
| 2023 Q1 | 988.04 Million CNY | 7.71% |
| 2023 FY | - CNY | -8.01% |
| 2023 Q4 | 473.02 Million CNY | 0.0% |
| 2023 Q3 | 473.02 Million CNY | -52.12% |
| 2023 Q2 | 988.04 Million CNY | 0.0% |
| 2022 Q1 | 963.47 Million CNY | 19.04% |
| 2022 FY | - CNY | 7.01% |
| 2022 Q4 | 917.3 Million CNY | 0.0% |
| 2022 Q3 | 917.3 Million CNY | -4.79% |
| 2022 Q2 | 963.47 Million CNY | 0.0% |
| 2021 Q3 | 809.35 Million CNY | -6.88% |
| 2021 FY | - CNY | 15.22% |
| 2021 Q1 | 869.18 Million CNY | 14.21% |
| 2021 Q4 | 809.35 Million CNY | 0.0% |
| 2021 Q2 | 869.18 Million CNY | 0.0% |
| 2020 Q3 | 761.03 Million CNY | 5.83% |
| 2020 FY | - CNY | 13.71% |
| 2020 Q1 | 719.13 Million CNY | 17.15% |
| 2020 Q2 | 719.13 Million CNY | 0.0% |
| 2020 Q4 | 761.03 Million CNY | 0.0% |
| 2019 Q1 | 661.32 Million CNY | 25.81% |
| 2019 Q3 | 613.85 Million CNY | -7.18% |
| 2019 Q4 | 613.85 Million CNY | 0.0% |
| 2019 FY | - CNY | 21.37% |
| 2019 Q2 | 661.32 Million CNY | 0.0% |
| 2018 Q2 | 574.35 Million CNY | 0.0% |
| 2018 Q4 | 525.65 Million CNY | 0.0% |
| 2018 FY | - CNY | 8.39% |
| 2018 Q1 | 574.35 Million CNY | 14.14% |
| 2018 Q3 | 525.65 Million CNY | -8.48% |
| 2017 Q1 | 532.08 Million CNY | 17.29% |
| 2017 FY | - CNY | 20.01% |
| 2017 Q4 | 503.21 Million CNY | 0.0% |
| 2017 Q3 | 503.21 Million CNY | -5.43% |
| 2017 Q2 | 532.08 Million CNY | 0.0% |
| 2016 FY | - CNY | 49.03% |
| 2016 Q1 | 392.49 Million CNY | 37.7% |
| 2016 Q2 | 392.49 Million CNY | 0.0% |
| 2016 Q3 | 453.64 Million CNY | 15.58% |
| 2016 Q4 | 453.64 Million CNY | 0.0% |
| 2015 Q4 | 285.02 Million CNY | 0.0% |
| 2015 FY | - CNY | -2.02% |
| 2015 Q2 | 273.47 Million CNY | 0.0% |
| 2015 Q1 | 273.47 Million CNY | 14.4% |
| 2015 Q3 | 285.02 Million CNY | 4.23% |
| 2014 Q2 | 217.97 Million CNY | 0.0% |
| 2014 Q1 | 217.97 Million CNY | 33.53% |
| 2014 FY | - CNY | 64.23% |
| 2014 Q4 | 239.04 Million CNY | 0.0% |
| 2014 Q3 | 239.04 Million CNY | 9.67% |
| 2013 Q3 | 163.23 Million CNY | 0.96% |
| 2013 Q4 | 163.23 Million CNY | 0.0% |
| 2013 FY | - CNY | 14.23% |
| 2013 Q1 | 161.68 Million CNY | 10.91% |
| 2013 Q2 | 161.68 Million CNY | 0.0% |
| 2012 FY | - CNY | 38.05% |
| 2012 Q2 | - CNY | -100.0% |
| 2012 Q1 | 185.91 Million CNY | 0.0% |
| 2012 Q3 | 147.04 Million CNY | 0.0% |
| 2012 Q4 | 145.77 Million CNY | -0.86% |
| 2011 Q2 | - CNY | 0.0% |
| 2011 FY | - CNY | 88.35% |
| 2011 Q4 | - CNY | 0.0% |
| 2010 FY | - CNY | 25.08% |
| 2010 Q4 | - CNY | 0.0% |
| 2010 Q2 | - CNY | 0.0% |
| 2009 FY | - CNY | 45.81% |
| 2008 FY | - CNY | 65.79% |
| 2007 FY | - CNY | 73.34% |
| 2006 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 150.4 Million HKD | -1842.918% |
| Grand Pharmaceutical Group Limited | 2.96 Billion HKD | 1.497% |
| Extrawell Pharmaceutical Holdings Limited | -129.51 Million HKD | 2356.137% |
| Wai Yuen Tong Medicine Holdings Limited | 113.79 Million HKD | -2467.839% |
| Qianhai Health Holdings Limited | -50.22 Million HKD | 5917.653% |
| Lee's Pharmaceutical Holdings Limited | 109.82 Million HKD | -2560.853% |
| Essex Bio-Technology Limited | 418.37 Million HKD | -598.449% |
| Tongfang Kontafarma Holdings Limited | 76.63 Million HKD | -3713.173% |
| PuraPharm Corporation Limited | -26.16 Million HKD | 11266.453% |
| SSY Group Limited | 2.11 Billion HKD | -38.192% |
| JBM (Healthcare) Limited | 204.39 Million HKD | -1329.693% |
| Jacobson Pharma Corporation Limited | 429.92 Million HKD | -579.694% |
| China Resources Pharmaceutical Group Limited | 15.43 Billion HKD | 81.063% |